Posted by Presse
Picture Gallery, Venture Capital
Friday, February 10th, 2017
CEO to review dronabinol, a Phase 3-ready medicine for the treatment of obstructive sleep apnea, and provide pipeline update
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Friday, December 23rd, 2016
GLEN ROCK, NJ — (Marketwired) — 12/23/16 — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), is pleased to announce positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial, a Phase 2B study of dronabinol for the treatment of obstructive sleep apnea ("OSA"), clearly demonst